Gunderson Dettmer client Sherlock Biosciences, a company developing CRISPR application methods to make molecular diagnostics more accessible, has raised over $31M in Series A funding from Northpond Ventures, Baidu Ventures, the Open Philanthropy Project and other investors. The fresh capital will be used to advance development programs for Sherlock’s core platform technologies.

In the announcement of the deal Sherlock’s co-founder, president and CEO Rahul K. Dhanda said, “We are delighted to have the backing of Northpond Ventures, Baidu Ventures, and our additional investors as we advance our core technologies to develop better, faster, more accurate diagnostic tests. Their support will be vital as we work to harness and direct the power of our SHERLOCK and INSPECTR platforms to develop rapid and more effective diagnostic tests through Engineering Biology and Deep Learning tools that can be performed anywhere, such as testing in the field or home.”

The Gunderson Dettmer deal team was led by Tim Ehrlich and included George Pothoulakis, Stephen Damato and Ruchir Patel.